ArticleCancer discovery2017
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 164 citations in OpenAlex.
- Loss ofJCO precision oncology · 2021Trial
- Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.Communications medicine · 2026Article
- Mathematical modeling of ribosome competition informs testable treatment strategies for drug-tolerant cancer persister cells.iScience · 2026Article
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- Therapy-Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.The Journal of clinical investigation · 2025Article
- NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition.Oncogene · 2025Article
- Transcriptome-wide decoding the roles of aberrant splicing in melanoma MAPK-targeted resistance evolution.EMBO reports · 2025Article
- Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.Molecular cancer · 2025Review
- Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.Journal for immunotherapy of cancer · 2025Article
- Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: implications for the involvement of pirin.Frontiers in pharmacology · 2025Article
- Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.Cancer research communications · 2025Article
- Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.Nature reviews. Cancer · 2024Review
- Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression.International journal of molecular sciences · 2024Review
- TransCell: In Silico Characterization of Genomic Landscape and Cellular Responses by Deep Transfer Learning.Genomics, proteomics & bioinformatics · 2024Article
- The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.The Journal of clinical investigation · 2024Article
- MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Drug-tolerant persister cells in cancer: the cutting edges and future directions.Nature reviews. Clinical oncology · 2023Review
- Understanding cancer drug resistance withiScience · 2023Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Chunying SongDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Marco PivaDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Lu SunDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Aayoung HongDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Gatien MoriceauDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Xiangju KongDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Hong ZhangDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Shirley LomeliDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Jin QianDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Clarissa C YuDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Robert DamoiseauxDavid Geffen School of Medicine, University of California, Los Angeles, California.
Mark C KelleyDepartment of Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Kimberley B DahlmanDepartment of Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Philip O ScumpiaDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Jeffrey A SosmanDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Douglas B JohnsonDepartment of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Antoni RibasDavid Geffen School of Medicine, University of California, Los Angeles, California.
Willy HugoDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California.
Roger S LoDivision of Dermatology, Department of Medicine, University of California, Los Angeles, California. rlo@mednet.ucla.edu.
University of California, Los Angeles · USVanderbilt University · USBreast Cancer Research Foundation · US
Funding
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2013 to 2017
$8.4MPreventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceR01CA176111 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROGER S LO · 2013 to 2026
$5.4MNCI NIH HHS K12 CA090625NCI NIH HHS P01 CA168585NCI NIH HHS R01 CA176111
Abstract
Treatment of advanced
Indexed as
AnimalsCell Line, TumorDrug Resistance, NeoplasmHumansIndolesLeukocyte Common AntigensMAP Kinase Kinase 1MelanomaMelanoma, ExperimentalMiceMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesTranscriptomeBRAF protein, humanIndolesLeukocyte Common AntigensMAP Kinase Kinase 1Protein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.